2024 American Society of Clinical Oncology (ASCO)
ASCO 2024 Prostate Cancer
- ASCO 2024: Validation of a Digital Pathology-Based Multimodal Artificial Intelligence Model in Oligometastatic Castration-Sensitive Prostate Cancer, Including in Patients from the STOMP and ORIOLE Phase II Randomized Clinical Trials
- ASCO 2024: Using Artificial Intelligence to Optimize Systemic Therapy for Prostate Cancer
- ASCO 2024: Artificial Intelligence and Deep Learning in Prostate Cancer Pathology
- ASCO 2024: Artificial Intelligence: Innovation and Potential for Diagnostic Imaging in Prostate Cancer
- ASCO 2024: Patient-Centered Approaches to Improve Quality of Life and Mitigate the Adverse Effects of Androgen Deprivation Therapy
ASCO 2024 Bladder Cancer
- ASCO 2024: What Is Variant Histology Urothelial Cancer and What Are the Available Treatment Options?
- ASCO 2024: Phase II Trial of Intravesical Camrelizumab in BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer
- ASCO 2024: FGFR3 Alterations in Patients Who Develop Locally Advanced or Metastatic Urothelial Cancer, and Their Association with Tumor Subtype and Clinical Outcomes in Patients Treated with Erdafitinib Versus Pembrolizumab
- ASCO 2024: Considerations in Treating and Palliating Variant Genitourinary Cancers Where No Standard of Care Exists
- ASCO 2024: Cost-Effectiveness Analysis of Contemporary First-Line Agents in Locally Advanced/metastatic Urothelial Carcinoma
ASCO 2024 Kidney Cancer
- ASCO 2024: What Is Variant Histology Renal Cell Cancer and What Are the Available Treatment Options?
- ASCO 2024: Phase 1b/2 Study of Combination 177Lu Girentuximab plus Cabozantinib and Nivolumab in Treatment Naive Patients with Advanced Clear Cell RCC
- ASCO 2024: Discussion: The Needle in the Haystack: Finding Biomarkers in Kidney Cancer
- ASCO 2024: Biomarker Analyses in Patients with Advanced Renal Cell Carcinoma from the Phase 3 CLEAR Trial
- ASCO 2024: Biomarker Analysis of the Phase 3 KEYNOTE-426 Study of Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma